IL17A and psoriatic arthritis: Secukinumab (AIN457) is a fully human, anti-IL-17A monoclonal antibody indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult patients who have shown an inadequate response to previous treatments with disease-modifying antirheumatic drugs (DMARDs), axial spondyloarthritis (AxSpA), and active AS in adults who have not responded adequately to conventional treatment and non-radiographic axial spondyloarthritis (nr-AxSpA) [123,124].